These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9291171)

  • 21. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.
    Lewańska M; Siger-Zajdel M; Selmaj K
    Eur J Neurol; 2002 Nov; 9(6):565-72. PubMed ID: 12453070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG; Catz I; Ferenczi LZ; Krantz MJ
    Eur J Neurol; 2006 Aug; 13(8):887-95. PubMed ID: 16879301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study.
    Jablonowska B; Selbing A; Palfi M; Ernerudh J; Kjellberg S; Lindton B
    Hum Reprod; 1999 Mar; 14(3):838-41. PubMed ID: 10221723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.
    Bornstein MB; Miller A; Slagle S; Weitzman M; Drexler E; Keilson M; Spada V; Weiss W; Appel S; Rolak L
    Neurology; 1991 Apr; 41(4):533-9. PubMed ID: 2011253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulins in multiple sclerosis.
    Lisak RP
    Neurology; 1998 Dec; 51(6 Suppl 5):S25-9. PubMed ID: 9851727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Tourbah A; Lebrun-Frenay C; Edan G; Clanet M; Papeix C; Vukusic S; De Sèze J; Debouverie M; Gout O; Clavelou P; Defer G; Laplaud DA; Moreau T; Labauge P; Brochet B; Sedel F; Pelletier J;
    Mult Scler; 2016 Nov; 22(13):1719-1731. PubMed ID: 27589059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.
    Kalanie H; Gharagozli K; Hemmatie A; Ghorbanie M; Kalanie AR
    Eur Neurol; 2004; 52(4):202-6. PubMed ID: 15539773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis.
    Stangel M; Boegner F; Klatt CH; Hofmeister C; Seyfert S
    J Neurol Neurosurg Psychiatry; 2000 Jan; 68(1):89-92. PubMed ID: 10601410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study").
    Aggarwal R; Charles-Schoeman C; Schessl J; Dimachkie MM; Beckmann I; Levine T
    Medicine (Baltimore); 2021 Jan; 100(1):e23677. PubMed ID: 33429735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
    Hahn AF; Beydoun SR; Lawson V; ; Oh M; Empson VG; Leibl H; Ngo LY; Gelmont D; Koski CL
    J Peripher Nerv Syst; 2013 Dec; 18(4):321-30. PubMed ID: 24725024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intravenous immunoglobulin in the treatment of multiple sclerosis.
    Sorensen PS
    J Neurol Sci; 2003 Feb; 206(2):123-30. PubMed ID: 12559498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.
    Ann Neurol; 1990 Jun; 27(6):591-605. PubMed ID: 2193613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH; Dahlke F; Thompson AJ; Ghazi M; Kappos L; Miltenburger C; Pozilli C
    Mult Scler; 1995; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.
    Comi G; Roveri L; Swan A; Willison H; Bojar M; Illa I; Karageorgiou C; Nobile-Orazio E; van den Bergh P; Swan T; Hughes R; Aubry J; Baumann N; Hadden R; Lunn M; Knapp M; Léger JM; Bouche P; Mazanec R; Meucci N; van der Meché F; Toyka K;
    J Neurol; 2002 Oct; 249(10):1370-7. PubMed ID: 12382151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.